Breaking news

Isomorphic Labs Secures $600 Million To Revolutionize Drug Discovery With AI

Isomorphic Labs, the trailblazing AI-driven drug discovery startup, has successfully raised $600 million in its inaugural funding round. The Series A round, spearheaded by Thrive Capital, also saw continued backing from Alphabet’s Google Ventures, marking a significant milestone for the company.

Why This Matters

With AI rapidly becoming the core of innovation in nearly every tech sector, Isomorphic Labs is tapping into the booming intersection of artificial intelligence and pharmaceuticals. As demand for AI-powered solutions surges, particularly in drug development, this latest investment highlights the growing importance of AI in reshaping the life sciences industry.

The Backstory

Founded in 2021, Isomorphic Labs emerged from Google’s renowned AI research division, DeepMind. The company builds on DeepMind’s groundbreaking advancements, including the Nobel-winning “AlphaFold” model, which accurately predicts protein structures—critical to understanding diseases and developing new drugs. Isomorphic’s work represents the next frontier in AI-powered medicine.

Looking Ahead

The newly secured capital will fuel the company’s R&D ambitions and accelerate its talent acquisition. Founder and CEO Demis Hassabis, who also heads DeepMind, has ambitious plans. He aims for Isomorphic Labs to have AI-designed drugs entering clinical trials by the end of 2025—a timeline that underscores both the company’s potential and the immense promise of AI in revolutionizing drug discovery.

This $600 million funding round not only signals strong investor confidence but also cements Isomorphic Labs’ position at the forefront of the AI pharmaceutical revolution.

EU E-Commerce VAT Systems Generate €257.9 Million Revenue for Cyprus in 2024

Robust Revenue Growth Through Streamlined VAT Collection

Cyprus has demonstrated a significant fiscal boost in 2024 with €257.9 million generated from the European Union’s e-commerce VAT systems, according to Tax Commissioner Sotiris Markides. This impressive performance underscores the effectiveness of the One Stop Shop (OSS) and Import One Stop Shop (IOSS) frameworks in simplifying cross-border tax compliance.

Simplified Procedures for EU and Non-EU Businesses

The OSS system allows Cyprus-registered businesses to streamline VAT declaration and payment on sales to consumers in other EU countries. Companies simply register on the local OSS platform, apply the consumer’s VAT rate, aggregate their submissions quarterly or monthly, and remit a single consolidated payment. Subsequently, Cyprus allocates the appropriate share to each respective EU country. This efficient process extends to non-EU sellers as well, who can have their intra-EU distance sales managed under the Union Scheme.

Breakdown of VAT Revenue Streams

Last year’s declarations under the various schemes illustrate the system’s broad reach: €217.9 million was collected via the Union Scheme, €36.9 million through the Non-Union Scheme, and €3.1 million via the Import Scheme. While the Union Scheme caters to both EU and non-EU sellers engaging in distance sales, the Non-Union Scheme specifically accommodates non-EU firms delivering services to EU consumers. Furthermore, the Import Scheme targets goods valued at less than €150 that are imported from outside the EU.

Implications and Broader Impact

Implemented in July 2021 as an evolution from the more limited MOSS system, these reforms have not only consolidated tax collection through an expansive OSS but also integrated the IOSS for low-value imports. By designating certain online marketplaces as “deemed suppliers,” the new framework ensures that VAT collection is both efficient and equitable. Across the EU, these mechanisms have generated over €33 billion in VAT revenues in 2024, reflecting a successful effort to simplify tax compliance, reduce administrative burdens, and promote fair taxation across the bloc.

The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter